Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Corrected: BRIEF-Oryzon Presents Data For Iadademstat Combinations In AML Patients

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    09/12/2025 07:30
    Corrects fourth bullet to say 'remissions' not 'responses'; fixes metadata.

Dec 9 (Reuters) - Oryzon Genomics SA ORY.MC:

PRESENTS UPDATED DATA ON IADADEMSTAT

100% GLOBAL RESPONSE RATE IN AML STUDY WITH AZACITIDINE AND VENETOCLAX

IADADEMSTAT TREATMENT SAFE AND WELL TOLERATED

80% COMPLETE REMISSIONS AND 90% COMPOSITE COMPLETE REMISSIONS RATE

MEDIAN OVERALL SURVIVAL NOT REACHED AFTER 9 MONTHS AND GOOD TOLERABILITY

Source text

Further company coverage: ORY.MC

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on ORYZON Genomics SA

    See all news